Author

Teuvo L.J. Tammela

Tampere UniversityORCID 0000-0002-3529-4649Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:statistical model· 4 Assay:GWAS summary statistics· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

Ian Geoffrey MillsiD· 4 shared Adam Stuart KibeliD· 3 shared Agnieszka MichaeliD· 3 shared Ali Amin Al OlamaiD· 3 shared Amanda B. SpurdleiD· 3 shared Anders Martin DaleiD· 3 shared Børge Grønne NordestgaardiD· 3 shared Cezary CybulskiiD· 3 shared

Activity by Year

2016-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersGenetics

Ian Geoffrey MillsORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Phenotypic and transcriptomic characterization of bicalutamide and enzalutamide resistance in castration-resistant prostate cancer cells

Reetta Nätkin, Milja I. Paloneva, Paavo V. H. Raittinen, Heimo Syvälä, Merja Bläuer, Teuvo L.J. Tammela, Pauliina Ilmonen, Matti Nykter, Aino Siltari, Teemu Johannes Murtola

This study characterizes transcriptomic and phenotypic changes in prostate cancer cells developing resistance to bicalutamide and enzalutamide, showing treatment sequence affects drug resistance and docetaxel sensitivity.

bioRxiv · May 30, 2025 · PreprintCancer Biology

Immunosuppression in the prostate tumor microenvironment is tied to androgen deprivation therapy-resistant club-like cells

Antti Kiviaho, Sini K. Eerola, Heini M. L. Kallio, Maria K. Andersen, Miina Hoikka, Aliisa M. Tiihonen, Iida Salonen, Xander Spotbeen, Alexander Giesen, Charles T. A. Parker, Sinja Taavitsainen, Olli Hantula, Mikael Marttinen, Ismaïl Hermelo, Mazlina Ismail, , Matti Nykter

The paper identifies club-like cells in the prostate tumor microenvironment that contribute to androgen deprivation therapy resistance through immune suppression.

Nature Communications · Nov 16, 2024Peer-reviewedCancer Biology

The effect of sample size on polygenic hazard models for prostate cancer

Roshan A. Karunamuni, Minh‐Phuong Huynh‐Le, Chun Chieh Fan, Rosalind A. Eeles, Douglas F. Easton, Zsofia Kote‐Jarai, Ali Amin Al Olama, Sara Benlloch Garcia, Kenneth Ross Muir, Henrik Grönberg, Fredrik E. Wiklund, Markus Aly, Johanna Schleutker, Csilla Sipeky, Teuvo L.J. Tammela, , Tyler M. Seibert

This paper evaluates how sample size affects polygenic hazard score models for prostate cancer, finding that 20-30k samples are needed for discovery models, but 10k suffice if SNPs are pre-established.

European Journal of Human Genetics · Jun 8, 2020Peer-reviewedGenetics

A genetic hazard score to personalize prostate cancer screening, applied to population data

Minh‐Phuong Huynh‐Le, Chun Chieh Fan, Roshan A. Karunamuni, Eleanor I. Walsh, Emma L. Turner, J. Athene Lane, Richard Michael Martin, David Edgar Neal, Jenny Donovan, Freddie Charles Hamdy, John Kellogg Parsons, Rosalind A. Eeles, Douglas F. Easton, Zsofia Kote‐Jarai, Ali Amin Al Olama, , Tyler M. Seibert

The paper evaluates a polygenic hazard score for prostate cancer screening, showing it improves positive predictive value by adjusting screening age based on genetic risk.

bioRxiv · Apr 26, 2019 · PreprintGenetics

A genetic risk score to guide age-specific, personalized prostate cancer screening

Tyler M. Seibert, Chun Chieh Fan, Yunpeng Wang, Verena Zuber, Roshan A. Karunamuni, John Kellogg Parsons, Rosalind A. Eeles, Douglas F. Easton, Zsofia Kote‐Jarai, Ali Amin Al Olama, Sara Benlloch Garcia, Kenneth Ross Muir, Henrik Grönberg, Fredrik E. Wiklund, Markus Aly, , Anders Martin Dale

This paper develops a genetic risk score to personalize prostate cancer screening age based on polygenic hazard scores and validates its predictive power in a separate dataset.

bioRxiv · Nov 25, 2016 · PreprintGenetics